Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the anti-inflammatory agent. Friday, Sanofi reported that Dupixent had set a ...

Sanofi SAN-0.20%decrease; red down pointing triangle said a jump in sales of its blockbuster Dupixent drug and robust pharmaceutical launches drove higher revenue and adjusted earnings for the third ...

Sanofi delivered strong Q3 results despite currency headwinds. The company's dependence on Dupixent is increasing. A broad immunology pipeline and the Blueprint Medicines acquisition should help ...

Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with nasal polyps (CRSwNP), a second biologic therapy has broken through with a ...

Sanofi SNY reported third-quarter 2025 adjusted earnings of $1.70 per American depositary share, which beat the Zacks Consensus Estimate of $1.60. Earnings of €2.91 per share rose 7% on a reported ...

Sanofi (NASDAQ:SNY) shares traded slightly higher in Paris on Friday after the French drugmaker reported better-than-expected Q3 2025 financial results, thanks mainly to its asthma drug Dupixent, ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the drug ...

Revenue: EUR12.4 billion in Q3 2025, up 7% year-over-year. DUPIXENT Sales: EUR4 billion in quarterly sales, marking a new milestone. New Launches Sales: EUR1.8 billion, representing 15% of total sales ...

Sanofi said a jump in sales of its blockbuster Dupixent drug and robust pharmaceutical launches drove higher revenue and adjusted earnings for the third quarter, as the company continues in talks with ...

LONDON, Oct 24 (Reuters) - Sanofi (SASY.PA), opens new tab reported stronger than expected third-quarter profit on Friday, boosted by demand for blockbuster asthma drug Dupixent, even as the French ...

(Reuters) -Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its eczema treatment, Dupixent, and cancer treatment Libtayo, sending ...

Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, Inc. REGN reports third-quarter 2025 results on Oct. 28, 2025. The Zacks ...